Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MIST 
Milestone Pharmaceuticals Inc (MIST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MIST (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.33
1 Year Target Price $3.33
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.87% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 153.84M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 4 | Beta 0.52 | 52 Weeks Range 0.62 - 2.75 | Updated Date 08/28/2025 |
52 Weeks Range 0.62 - 2.75 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.18 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.33% | Return on Equity (TTM) -780.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 163363763 | Price to Sales(TTM) 77.32 |
Enterprise Value 163363763 | Price to Sales(TTM) 77.32 | ||
Enterprise Value to Revenue 81.44 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 84964304 | Shares Floating 53456569 |
Shares Outstanding 84964304 | Shares Floating 53456569 | ||
Percent Insiders 3.37 | Percent Institutions 20.09 |
Upturn AI SWOT
Milestone Pharmaceuticals Inc
Company Overview
History and Background
Milestone Pharmaceuticals Inc. was founded in 2003 and is a biopharmaceutical company focused on the development and commercialization of innovative products for cardiovascular diseases. They have focused on developing Etripamil.
Core Business Areas
- Cardiovascular Therapeutics: Milestone Pharmaceuticals focuses on developing and commercializing therapies for cardiovascular conditions, primarily paroxysmal supraventricular tachycardia (PSVT).
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. Details on organizational structure would require internal company information.
Top Products and Market Share
Key Offerings
- Etripamil: Etripamil is a novel calcium channel blocker nasal spray being developed for the treatment of PSVT. Currently not approved, but could potentially disrupt the current treatment landscape if successful. Competitors include adenosine, verapamil, and diltiazem, administered intravenously in medical settings.
Market Dynamics
Industry Overview
The cardiovascular therapeutics market is a large and growing market, driven by the increasing prevalence of cardiovascular diseases. Competition is intense, with many established pharmaceutical companies.
Positioning
Milestone Pharmaceuticals aims to carve a niche by offering a non-invasive, self-administered treatment option for PSVT, potentially offering convenience and reducing the need for hospital visits.
Total Addressable Market (TAM)
The market for PSVT treatments is estimated to be significant, with millions of patients affected globally. Milestone aims to address the at-home acute treatment. Difficult to calculate the exact TAM, but their product has the potential to capture a meaningful portion of the market if approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Etripamil)
- Potential for a non-invasive treatment option
- Experienced management team
Weaknesses
- Dependence on the success of Etripamil
- Lack of revenue-generating products (pre-approval)
- Small market capitalization
Opportunities
- Potential for regulatory approval of Etripamil
- Expansion to other cardiovascular indications
- Partnerships with larger pharmaceutical companies
Threats
- Regulatory hurdles
- Competition from existing treatments
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- Bausch Health Companies Inc (BHC)
- Pfizer Inc (PFE)
- Merck & Co Inc (MRK)
Competitive Landscape
Milestone Pharmaceuticals aims to compete by offering a non-invasive alternative to existing intravenous treatments for PSVT. Their success hinges on demonstrating superior convenience and efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is measured by clinical trial progress and financings rather than revenue.
Future Projections: Future growth depends on the successful development and commercialization of Etripamil. Analyst estimates vary widely based on regulatory approval expectations.
Recent Initiatives: Recent initiatives include advancing Etripamil through Phase III clinical trials and seeking regulatory approval.
Summary
Milestone Pharmaceuticals is a pre-revenue biopharmaceutical company heavily reliant on the success of Etripamil. Positive clinical trial outcomes and regulatory approvals are critical for its growth. The company faces significant competition and financial risks, but its novel treatment approach offers considerable potential if approved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.milestonepharma.com |
Full time employees 33 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.